drugset / Trial / NCT06534320
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To Evaluate the Safety, Tolerability and Pharmacokinetics on DA-302168S Tablets in Randomized, Double-blind, Placebo-controlled Single-dose and Multiple-dose ascending Phase I Clinical Trials in Healthy Subjects.
Timeline
- Start
- 2024-04-18
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-302168S | Small molecule | 2.5 mg | — |
| Subject | DA-302168S | Small molecule | 7.5 mg | — |
| Subject | DA-302168S | Small molecule | 15 mg | — |
| Subject | DA-302168S | Small molecule | 30 mg | — |
| Subject | DA-302168S | Small molecule | 50 mg | — |
| Subject | DA-302168S | Small molecule | 75 mg | — |
| Subject | DA-302168S | Small molecule | 100 mg | — |